Evidence map›Paper›PMID 42743305›Full record

ArticlePloS one2026

Sino-US-DrugQA: A benchmark for evaluating large language models in cross-jurisdictional pharmaceutical regulation.

Xuejing Fu, Zhen Chen, Wentao Lu

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xuejing FuInformation Application Research Center of Shanghai Municipal Administration for Market Regulation, Shanghai, China.
Zhen ChenInformation Application Research Center of Shanghai Municipal Administration for Market Regulation, Shanghai, China.
Wentao LuShanghai Artificial Intelligence Research Institute Co., Ltd., Shanghai, China.ORCID https://orcid.org/0009-0000-0763-213X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cross-jurisdictional pharmaceutical compliance requires comparison of regulatory requirements across administrative systems such as the US Food and Drug Administration and China's National Medical Products Administration. Although large language models (LLMs) are increasingly explored for healthcare and regulatory applications, their performance in cross-jurisdictional pharmaceutical regulation has not been systematically evaluated using a dedicated benchmark. We introduce Sino-US-DrugQA, a bilingual multiple-choice benchmark covering Monolingual, Comparative, and Parallel regulatory question-answer tasks. The 11,871 candidate items underwent deterministic structural validation and full-dataset semantic quality screening, followed by risk-stratified independent review of 1,432 items by two regulatory experts. The final release comprised 11,444 items, including 10,122 classified as pass and 1,322 as borderline. Among 500 items sampled from the semantic screen-negative population, 18 were subsequently classified as material errors, corresponding to an observed residual material-error proportion of 3.60% (Wilson 95% confidence interval, 2.29%-5.62%). Four representative LLMs-gpt-5.6-terra, gemini-3.6-flash, deepseek-v4-flash, and qwen-3.5-max-were evaluated under a standardized zero-shot protocol. Overall accuracy ranged from 83.21% to 86.43%. Comparative accuracy was consistently lower than Monolingual accuracy, with absolute differences of 4.42-8.98 percentage points across models. The two highest-scoring models, GPT and Gemini, did not differ significantly after adjustment for multiple comparisons. These results indicate that explicit comparison across non-equivalent regulatory systems remains more challenging than single-jurisdiction question answering. Sino-US-DrugQA provides a validated and reproducible resource for evaluating bilingual regulatory reasoning. The findings support further investigation of expert-supervised decision-support workflows rather than autonomous regulatory interpretation. The stable dataset release and evaluation resources are available at https://github.com/DodgeLU/Sino-US-DrugQA.

Indexed as

BenchmarkingDrug and Narcotic ControlChinaHumansLarge Language ModelsUnited StatesUnited States Food and Drug Administration

Identifiers

PMID42743305
PMCPMC13577527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.